Clinical Study of 18F -FAPI-RGD in Renal Tumor

Status Recruiting

Clinical Trial Summary

The goal of this observational study is to learn about the value of 18F-FAPI-RGD PET/CT imaging in Renal Tumor. Participants will undergo clinical evaluation and 18F-FAPI-RGD PET/CT examination.

Clinical Trial Description

Early detection, accurate diagnosis and staging are the keys to effective treatment of kidney cancer patients.Pathological diagnosis is still the gold standard, but renal perforation is invasive examination, there are certain complications, the most common is bleeding and hematoma, rare renal arteriovenous fistula formation and infection.A non-invasive test with high accuracy is expected.68Ga-FAPI-04 has been reported to be superior to 18F-FDG in the study of bone metastases in RCC patients, and in addition to detecting more metastases than 18F-FDGPET/CT, uptake is 3-4 times higher than 18F-FDG.There are also many literatures reporting that APIPET/CT may be better than 18F-FDGPET/CT in the detection of various malignant tumors, and FAPI targeted imaging is a promising way in the diagnosis and treatment of papillary renal cell carcinoma. 18F-FPPRGD2PET/CT may be a useful tool for monitoring early response to anti-angiogenic therapy in patients with mRCC.18F-FPRGD2PET/CT reliably estimated the expression of integrin αvβ3 in renal tumors, and in clear cell RCC(ccRCC) groups, 18F-FPRGD2PET signal correlated with the expression of integrin αvβ3 in tumor cells.In the papillary RCC(pRCC) group, the signal was correlated with the expression of αvβ3.The expression of integrin αvβ3 in ccRCC cells was significantly higher than that in pRCC cells.These findings are consistent with results obtained with other RGD-based tracers in various cancers.The expression level of integrin αvβ3 in tumor cells is associated with invasiveness and metastasis potential, and quantifying it with PET may contribute to the study of integrin αvβ3 as a prognostic factor. Heterodimer peptide FAPI-RGD was synthesized from FAPI and RGD.FAPI-RGD is a heterodimeric peptide that targets FAP and αvβ3-integrin receptors, 68Ga-FAPI-RGDPET/CT imaging has been used in clinical imaging studies of patients with various tumors.So, we plan to use 18F-FAPI-RGD PET/CT imaging is used in the diagnosis and treatment of renal cancer, and preliminary experiments have confirmed that this examination has a good imaging effect. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05976607
Study type	Observational [Patient Registry]
Source	Sichuan Provincial People's Hospital
Contact
Status	Recruiting
Phase
Start date	June 20, 2023
Completion date	February 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03900364` - a Prospective Trial Comparing Robot-assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy	N/A
Completed	`NCT02862288` - Preliminary Study of Microwave Tumoral Ablation Performances for the Treatment of Pulmonary, Renal and Bone Neoplasia.	Phase 1/Phase 2
Enrolling by invitation	`NCT05115812` - Renal Autotransplantation; Case Series
Completed	`NCT04096534` - Normotonic Partial Nephrectomy as Novel Approach in Treating Small Renal Masses	N/A
Completed	`NCT04072224` - Evaluation of the Reproducibility of Ablation Volumes at One Month After Microwave Treatment Compared to the Manufacturer's Abacus: on the Kidney, Liver and Lung
Recruiting	`NCT03747133` - SABR for Renal Tumors	N/A
Recruiting	`NCT04506671` - Percutaneous Cryoablation Versus Partial Nephrectomy for T1b Renal Tumor	N/A
Recruiting	`NCT05377632` - Comparing Two Different Approaches in Robotic-Assisted Renal Surgery	N/A
Recruiting	`NCT03667885` - Non-Invasive Diagnostics of Small Renal Masses
Completed	`NCT03841149` - Volume 3D_US Kidney
Recruiting	`NCT06322745` - Thulium Beam Coagulation Versus Suture Renorrhaphy for Hemostasis of Tumor Bed in Laparoscopic Partial Nephrectomy	N/A
Terminated	`NCT02581384` - Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors	Phase 1/Phase 2
Completed	`NCT02335827` - Irreversible Electroporation(IRE) For Unresectable Renal Tumors	N/A
Completed	`NCT05089006` - Cost-effectivness of Robot-assisted Surgery Compared to Open Surgery for Partial Nephrectomy in Context of Renal Tumor
Recruiting	`NCT03810651` - Pencil Beam Scanning in Patients With Renal Tumors	Early Phase 1
Not yet recruiting	`NCT05572216` - A CCafU-UroCCR Randomized Trial: 3D Image-Guided Robot-AssisTEd Partial Nephrectomy for Renal Complex Tumor (UroCCR N°99)	N/A
Recruiting	`NCT06076538` - PET/MR for Characterization of Renal Masses (RMs)
Completed	`NCT01833728` - A Comparison of Nefopam-propacetamol Combination and Propacetamol for Postoperative Quality of Recovery After Laparoscopic Nephrectomy	N/A
Recruiting	`NCT04537247` - A Comparative Study Between Open and Robotic Partial Nephrectomy in Treatment of High Complex Renal Tumors.	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.